The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study
Abstract Background Metabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-03-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12888-018-1662-6 |
| _version_ | 1818282166837051392 |
|---|---|
| author | Samer Hammoudeh Suhaila Ghuloum Ziyad Mahfoud Arij Yehya Abdulmoneim Abdulhakam Azza Al-Mujalli Mahmoud Al-Zirie Mohamed Osman Abdel Rahman Angela Godwin Noura Younes Yahya Hani Dennis Mook-Kanamori Marjonneke Mook-Kanamori Reem El Sherbiny Hassen Al-Amin |
| author_facet | Samer Hammoudeh Suhaila Ghuloum Ziyad Mahfoud Arij Yehya Abdulmoneim Abdulhakam Azza Al-Mujalli Mahmoud Al-Zirie Mohamed Osman Abdel Rahman Angela Godwin Noura Younes Yahya Hani Dennis Mook-Kanamori Marjonneke Mook-Kanamori Reem El Sherbiny Hassen Al-Amin |
| author_sort | Samer Hammoudeh |
| collection | DOAJ |
| description | Abstract Background Metabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on antipsychotics relative to controls in Qatar, and to assess the factors contributing to the development of MetS. Methods A cross sectional design was used to collect data and fasting blood samples from subjects maintained on antipsychotics for at least six months (n = 112) and from a control group (n = 114). The groups were compared in regard to prevalence of MetS, and multiple regression analysis was used to determine the risk factors in each group. Results The two groups (antipsychotics vs. control) were similar in regard to age (35.73 ± 10.28 vs. 35.73 ± 8.16 years) and gender ratio. The MetS was higher among the subjects on antipsychotics, but this difference did not reach statistical significance. Blood pressure (BP) was significantly higher in the antipsychotics group and BMI was the major risk factor to develop MetS in this group. Conclusions The prevalence of MetS in both groups is high and mostly attributed to obesity and high BP. Public health interventions are needed to address this major health problem overall. Larger studies are needed to further assess the impact of antipsychotics and mental illness on the development of MetS. |
| first_indexed | 2024-12-13T00:16:42Z |
| format | Article |
| id | doaj.art-748babb50eca4eccb7407bc51668505d |
| institution | Directory Open Access Journal |
| issn | 1471-244X |
| language | English |
| last_indexed | 2024-12-13T00:16:42Z |
| publishDate | 2018-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Psychiatry |
| spelling | doaj.art-748babb50eca4eccb7407bc51668505d2022-12-22T00:05:46ZengBMCBMC Psychiatry1471-244X2018-03-011811910.1186/s12888-018-1662-6The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative studySamer Hammoudeh0Suhaila Ghuloum1Ziyad Mahfoud2Arij Yehya3Abdulmoneim Abdulhakam4Azza Al-Mujalli5Mahmoud Al-Zirie6Mohamed Osman Abdel Rahman7Angela Godwin8Noura Younes9Yahya Hani10Dennis Mook-Kanamori11Marjonneke Mook-Kanamori12Reem El Sherbiny13Hassen Al-Amin14Department of Research, Weill Cornell Medicine – QatarDepartment of Psychiatry, Rumailah Hospital, Hamad Medical CorporationDepartment of Health Policy and Research, Weill Cornell Medicine – QatarDepartment of Research, Weill Cornell Medicine – QatarDepartment of Psychiatry, Rumailah Hospital, Hamad Medical CorporationPrimary Health Care CorporationEndocrinology Department, Hamad General HospitalDepartment of Laboratory Medicine and Pathology, Hamad Medical CorporationDepartment of Laboratory Medicine and Pathology, Hamad Medical CorporationDepartment of Laboratory Medicine and Pathology, Hamad Medical CorporationDepartment of Psychiatry, Rumailah Hospital, Hamad Medical CorporationDepartment of Physiology and Biophysics, Weill Cornell Medicine – QatarDepartment of Physiology and Biophysics, Weill Cornell Medicine – QatarDepartment of Research, Weill Cornell Medicine – QatarDepartment of Psychiatry, Weill Cornell Medicine – QatarAbstract Background Metabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on antipsychotics relative to controls in Qatar, and to assess the factors contributing to the development of MetS. Methods A cross sectional design was used to collect data and fasting blood samples from subjects maintained on antipsychotics for at least six months (n = 112) and from a control group (n = 114). The groups were compared in regard to prevalence of MetS, and multiple regression analysis was used to determine the risk factors in each group. Results The two groups (antipsychotics vs. control) were similar in regard to age (35.73 ± 10.28 vs. 35.73 ± 8.16 years) and gender ratio. The MetS was higher among the subjects on antipsychotics, but this difference did not reach statistical significance. Blood pressure (BP) was significantly higher in the antipsychotics group and BMI was the major risk factor to develop MetS in this group. Conclusions The prevalence of MetS in both groups is high and mostly attributed to obesity and high BP. Public health interventions are needed to address this major health problem overall. Larger studies are needed to further assess the impact of antipsychotics and mental illness on the development of MetS.http://link.springer.com/article/10.1186/s12888-018-1662-6Metabolic syndromeAntipsychoticsArabsMental illness |
| spellingShingle | Samer Hammoudeh Suhaila Ghuloum Ziyad Mahfoud Arij Yehya Abdulmoneim Abdulhakam Azza Al-Mujalli Mahmoud Al-Zirie Mohamed Osman Abdel Rahman Angela Godwin Noura Younes Yahya Hani Dennis Mook-Kanamori Marjonneke Mook-Kanamori Reem El Sherbiny Hassen Al-Amin The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study BMC Psychiatry Metabolic syndrome Antipsychotics Arabs Mental illness |
| title | The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study |
| title_full | The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study |
| title_fullStr | The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study |
| title_full_unstemmed | The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study |
| title_short | The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study |
| title_sort | prevalence of metabolic syndrome in patients receiving antipsychotics in qatar a cross sectional comparative study |
| topic | Metabolic syndrome Antipsychotics Arabs Mental illness |
| url | http://link.springer.com/article/10.1186/s12888-018-1662-6 |
| work_keys_str_mv | AT samerhammoudeh theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT suhailaghuloum theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT ziyadmahfoud theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT arijyehya theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT abdulmoneimabdulhakam theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT azzaalmujalli theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT mahmoudalzirie theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT mohamedosmanabdelrahman theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT angelagodwin theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT nourayounes theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT yahyahani theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT dennismookkanamori theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT marjonnekemookkanamori theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT reemelsherbiny theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT hassenalamin theprevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT samerhammoudeh prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT suhailaghuloum prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT ziyadmahfoud prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT arijyehya prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT abdulmoneimabdulhakam prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT azzaalmujalli prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT mahmoudalzirie prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT mohamedosmanabdelrahman prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT angelagodwin prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT nourayounes prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT yahyahani prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT dennismookkanamori prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT marjonnekemookkanamori prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT reemelsherbiny prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy AT hassenalamin prevalenceofmetabolicsyndromeinpatientsreceivingantipsychoticsinqataracrosssectionalcomparativestudy |